摘要
利用互作蛋白质组化学技术发现G12D突变型KRAS相互作用化学分子。建立融合蛋白质表达量相同的BioID-G12D-KRAS与BioID-WTKRAS细胞,通过LC-MS/MS检测生物素化肽段,定量分析蛋白质组学数据,预测野生型KRAS和G12D突变型KRAS的潜在结合分子。最终成功培养BioID-G12D-KRAS和BioID-WT-KRAS表达含量相同的SW48细胞;定量质谱识别BioID-WT-KRAS组中有88个生物素化蛋白质,BioID-G12DKRAS组中有90个生物素化蛋白质;发现AHNAK2与野生型KRAS更稳定结合,SLC5A3与G12D突变型KRAS优势结合。
To globally discovery the molecules interacting with G12D mutant KRAS by the interaction proteomics technology.The cell system of BioID-G12D-KRAS and BioID-WT-KRAS with the same expression level of fusion protein was established.Biotinylated peptides were detected by LC-MS/MS,and then the proteomics data were quantitatively analyzed.Potential binding molecules of wild-type KRAS and G12D mutant KRAS were predicted.SW48 cells expressing BioID-G12D-KRAS and BioID-WT-KRAS separately were successfully cultured,and both cells expressed KRAS fusion protein in equal amounts.Quantitative mass spectrometry identified 88 biotinylated proteins in the BioID-WT-KRAS group.There were 90 biotinylated proteins in the BioID-G12D-KRAS group.It shows that ANHAK2 binds to KRAS more stably,and SLC5A3 tends to bind with G12D mutant KRAS.
作者
徐耀瑜
丁嘉颖
张雅慧
赵启程
张成杰
司伟杰
Xu Yaoyu;Ding Jiaying;Zhang Yahui;Zhao Qicheng;Zhang Chengjie;Si Weijie(College of Chemistry and Chemical Engineering,Anyang Normal University,He'nan,455000)
出处
《当代化工研究》
2022年第5期156-158,共3页
Modern Chemical Research
基金
河南省重点研发与推广专项(科技攻关)基金“突变KRAS导致的EGFR抑制剂耐药机制和靶点分子的发现研究”(项目编号:202102310345)
安阳市重点研发与推广专项(科技攻关)基金“乳腺癌药物palbociclib的潜在靶点研究”(项目编号:2022C 01SF089)
2020年安阳市科技发展计划专项基金“新型冠状病毒多联检测开发”(项目编号:2020年第3号)
2020年河南省教育厅平台中心类项目“河南省含氟药物精准合成工程技术研究中心”(项目编号:2020年第349号)。